Increasing the dose intensity of alemtuzumab (CAMPATH-1H) in chronic lymphocytic leukemia (CLL): The CAM1515 study

被引：0
|
作者：
Dyer, MJS
Buckby, E
Fermahan, P
Walewska, R
Kennedy, B
机构：
[1] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England
[2] Univ Leicester, Dept Haematol, Leicester, Leics, England
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2959
引用
收藏
页码：830A / 830A
页数：1
相关论文
共 50 条
  • [21] Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia
    Nabhan, C
    Rosen, ST
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 75 - 80
  • [22] Efficacy and tolerability of Alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia -: Change of regimen needed?
    Rieger, K
    Von Grünhagen, U
    Fietz, T
    Thiel, E
    Knauf, W
    LEUKEMIA & LYMPHOMA, 2004, 45 (02) : 345 - 349
  • [23] Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia - Efficacy of in vivo purging by alemtuzumab (Campath-1H)
    Galimberti, S
    Cervetti, G
    Cecconi, N
    Fazzi, R
    Pacini, S
    Guerrini, F
    Manetti, C
    Caracciolo, F
    Petrini, M
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (05) : 389 - 393
  • [24] A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) study 19901.
    Rai, KR
    Byrd, JC
    Peterson, BL
    Larson, RA
    BLOOD, 2002, 100 (11) : 205A - 206A
  • [25] Phase I study of rituximab and CAMPATH-1H in patients with relapsed or refractory chronic lymphocytic leukemia.
    Nabhan, C
    Tallman, MS
    Riley, MB
    Fitzpatrick, J
    Gordon, LI
    Gartenhaus, R
    Kuzel, T
    Siegel, R
    Rosen, ST
    BLOOD, 2001, 98 (11) : 365A - 365A
  • [26] Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia
    Nguyen, DD
    Cao, TM
    Dugan, K
    Starcher, SA
    Fechter, RL
    Coutre, SE
    CLINICAL LYMPHOMA, 2002, 3 (02): : 105 - 110
  • [27] Subcutaneous Campath-1H (Alemtuzumab) in fludarabine-refractory CLL interim analysis of the CLL2h study of the German CLL study group (GCLLSG).
    Stilgenbauer, S
    Winkler, D
    Kröber, A
    Kienle, D
    Hallek, M
    Hensel, M
    Lengfelder, E
    Trümper, L
    Dreger, P
    Jäger, U
    Döhner, H
    BLOOD, 2004, 104 (11) : 140A - 140A
  • [28] Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection
    Heider, U
    Fleissner, C
    Zavrski, I
    Jakob, C
    Dietzel, T
    Eucker, J
    Ockenga, J
    Possinger, K
    Sezer, O
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 72 (01) : 64 - 66
  • [29] Single-center experience of Campath® (alemtuzumab) treatment of refractory chronic lymphocytic leukemia (CLL) patients.
    Saba, HI
    Morelli, GA
    Tannenbaum, B
    Loughran, TP
    BLOOD, 2002, 100 (11) : 365B - 365B
  • [30] Efficacy of subcutaneous Alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL:: CLL2H study of the German CLL Study Group (GCLLSG)
    Stilgenbauer, S
    Kröber, A
    Winkler, D
    Kienle, D
    Busch, R
    Hallek, M
    Hensel, M
    Lengfelder, E
    Trümper, L
    Dreger, P
    Jäger, U
    Döhner, H
    ANNALS OF ONCOLOGY, 2005, 16 : 43 - 43
12345